About Rituximab (MABTHERA)
            
            Class: | Monoclonal antibody (anti-CD20)  
Use: | Treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis (GPA)  
Adult dose: | 375 mg/m² IV infusion once weekly for 4 weeks for NHL; 500 mg IV infusion on day 1 and 15 for CLL; 1000 mg IV infusion on day 1, 15, and 28 for RA; dosing may vary based on specific indication and treatment protocol  
Pediatric dose: | Not established; use in pediatric populations shoul
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (anti-CD20)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis (GPA)
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: F. Hoffmann-La Roche Ltd., SWITZERLAND
                    
                    
                    Package Size
                    20ml Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 11711.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        375 mg/m² IV infusion once weekly for 4 weeks for NHL; 500 mg IV infusion on day 1 and 15 for CLL; 1000 mg IV infusion on day 1, 15, and 28 for RA; dosing may vary based on specific indication and treatment protocol
                    
                    
                        Pediatric Dose
                    
                    
                        Not established; use in pediatric populations should be based on clinical judgment and specific protocols
                    
                 
                
                
                    
                        Side Effects
                    
                    Infusion reactions, infections, neutropenia, thrombocytopenia, fatigue, fever, chills, nausea, and rash
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to rituximab or any component of the formulation; active severe infections; history of progressive multifocal leukoencephalopathy (PML)
         
        
        
            
                Important Warnings
            
            Risk of severe infusion reactions, infections (including PML), and tumor lysis syndrome; monitor for signs of infection and infusion-related reactions; premedication with antihistamines and/or corticosteroids may be required to reduce infusion reactions
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.